Login / Signup

Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.

Ahmed FnaicheHwai-Chien ChanAlexis PaquinNarjara González SuárezVictoria VuFengling LiAbdellah Allali-HassaniMichelle Ada CaoMagdalena M SzewczykAlbina BolotokovaFrédéric AllemandMuriel GelinDalia Barsyte-LovejoyVijayaratnam SanthakumarMasoud VedadiJean-François GuichouBorhane AnnabiAlexandre Gagnon
Published in: ACS medicinal chemistry letters (2023)
The transcription factor YAP-TEAD is the downstream effector of the Hippo pathway which controls cell proliferation, apoptosis, tissue repair, and organ growth. Dysregulation of the Hippo pathway has been correlated with carcinogenic processes. A co-crystal structure of TEAD with its endogenous ligand palmitic acid (PA) as well as with flufenamic acid (FA) has been disclosed. Here we report the development of HC-258, which derives from FA and possesses an oxopentyl chain that mimics a molecule of PA as well as an acrylamide that reacts covalently with TEAD's cysteine. HC-258 reduces the CTGF , CYR61 , AXL , and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells. Co-crystallization with hTEAD2 confirmed that HC-258 binds within TEAD's PA pocket, where it forms a covalent bond with its cysteine.
Keyphrases